has been cited by the following article(s):
[1]
|
No increased bleeding events in patients with relapsed chronic lymphocytic leukemia and indolent non-Hodgkin lymphoma treated with idelalisib
Leukemia & Lymphoma,
2020
DOI:10.1080/10428194.2020.1845339
|
|
|
[2]
|
Patients’ priorities in selecting chronic lymphocytic leukemia treatments
Blood Advances,
2017
DOI:10.1182/bloodadvances.2017007294
|
|
|
[3]
|
Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma
Future Oncology,
2016
DOI:10.2217/fon-2016-0003
|
|
|
[4]
|
Phage Display Engineered T Cell Receptors as Tools for the Study of Tumor Peptide–MHC Interactions
Frontiers in Oncology,
2015
DOI:10.3389/fonc.2014.00378
|
|
|